China Resources will acquire a majority state in GenesisCare, Australia’s largest provider of radiation oncology and cardiology services, at a $1.3 billion valuation; Genexine, a Korean biotech, raised $70 million from investors including its China partner Tasly Pharma; Jilin Zixin Pharma paid $42 million for a 67% stake in Nabsys 2.0, a US company with a genome mapping technology; DiaMedica, a US-Canada biopharma, raised $4 million from a group that included Fosun Pharma; Zhejiang Hisun Pharma in-licensed China rights to pritumumab, a cancer mAb from Nascent Biotech of Florida; China started the world’s first clinical trial using CRISPR gene editing techniques; GSK announced China approval for Cervarix™, a human papillomavirus vaccine; and Sinopharm, China’s largest state-owned pharma, has submitted a plan that will make the company more independent of government control.
